Abstract
Multidrug resistance (MDR) in cancer is a prime obstacle toward successful cancer chemotherapy which is the combination of the complicated mechanisms involving abnormal vasculature, localized area of hypoxia, upregulated ABC transporters, aerobic glycolysis, elevated apoptotic threshold, and increased interstitial fluid pressure. Nanomedicines in targeted cancer chemotherapy hold great promise as an effective approach to prevail over MDR. Extensive research has been conducted to get success in development of Nanomedicines against MDR that introduced many of them as personalized medicine and in different clinical stages. Nanomedicines can be preferentially accumulated in tumor areas by EPR and by active targeting of upregulated processes such as ABC transporters of cancer cells. In this review, we aimed to discuss different nanomedicines that showed promises against MDR in cancer and improved the chemotherapeutic efficacy in the last decade. Moreover, different cellular and physiological factors that underlie MDR in cancer will also be discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
